Clinical characteristics and treatment of perianal fistulising Crohn's disease in Colombia: Results of a multicentric registry.

Características clínicas y tratamiento de la enfermedad de Crohn perianal fistulizante en Colombia: resultados de un registro multicéntrico.

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 16 01 2022
revised: 22 02 2022
accepted: 28 02 2022
pubmed: 13 3 2022
medline: 9 11 2022
entrez: 12 3 2022
Statut: ppublish

Résumé

Perianal fistulizing Crohn's disease (CD) is a phenotype with a poor prognosis. There are no studies in our country. Our objective is to determine the clinical, sociodemographic and treatment characteristics of perianal fistulizing CD in a Colombian multicenter registry. A retrospective, multicenter observational study was carried out, with prospective data collection, in the main reference centers for inflammatory Bowel disease (IBD) in the country. Continuous variables were expressed as medians and interquartile ranges. The categorical outcome variables were compared by the Chi-square test. Sixty-five patients with perianal fistulizing CD were documented, with a median age of appearance of perianal fistula of 31.0 years (range: 24-42), predominantly in men (61.5%; H:M ratio: 1.4:1). Complex perianal fistulas were more frequent than simple ones (75.35 vs. 24.6%). Regarding medical treatment, 66.2% of the patients received antibiotics, 64.6% steroids, 78.5% biological therapy, 47.7% non-cutting setons, and 46.2% required surgical management, other than seton placement. Only 29.2% achieved complete remission of the fistula, and 9.2% of the patients ended up in a definitive colostomy. CD patients with complex fistulas received more biological therapy, compared to CD patients with simple fistulas (84.8 vs. 56.3%; P: 0.038). Perianal fistulizing CD has a poor prognosis in our setting, only 3 out of 10 patients achieve complete remission despite treatment. A multidisciplinary management is essential for the comprehensive management of this difficult pathology.

Identifiants

pubmed: 35278506
pii: S0210-5705(22)00083-8
doi: 10.1016/j.gastrohep.2022.02.006
pii:
doi:

Substances chimiques

Infliximab B72HH48FLU
Antibodies, Monoclonal 0

Types de publication

Observational Study Multicenter Study Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

690-696

Informations de copyright

Copyright © 2022 Elsevier España, S.L.U. All rights reserved.

Auteurs

Fabian Juliao-Baños (F)

Hospital Pablo Tobón Uribe, Medellín, Colombia. Electronic address: fabianjuliao@hotmail.com.

Laura Osorio (L)

Unidad de Gastroenterología, Universidad CES, Medellín, Colombia.

Jhon Carvajal (J)

Hospital Pablo Tobón Uribe, Medellín, Colombia.

Gabriel Mosquera-Klinger (G)

Hospital Pablo Tobón Uribe, Medellín, Colombia.

Anwar Medellín (A)

Fundación Santa Fe de Bogotá, Bogotá, Colombia.

Jorge Padrón (J)

Fundación Santa Fe de Bogotá, Bogotá, Colombia.

Belén de Molano (B)

Fundación Santa Fe de Bogotá, Bogotá, Colombia.

Fabián Puentes (F)

Unión de Cirujanos, Manizales, Colombia.

Edwin Muñoz (E)

Unión de Cirujanos, Manizales, Colombia.

Gustavo Reyes (G)

Clínica Colombia, Bogotá, Colombia.

Fabio Gil (F)

Clínica Colombia, Bogotá, Colombia.

Viviana Parra-Izquierdo (V)

Gastroadvanced IPS, Bogotá, Colombia.

Héctor Sánchez (H)

Hospital Pablo Tobón Uribe, Medellín, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH